Q3 FY2026 · ended Sep 30, 2026 · Revenue $8.30B, +6.8% YoY · Filed Oct 30, 2026
Gilead Sciences, Inc. (GILD) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $8.3 billion and net income of $2.4 billion. Free cash flow was $4.8 billion. As of Sep 30, 2026 it held $6.4 billion in cash and investments and $26.2 billion in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GILD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882095
- Former names
- GILEAD SCIENCES INC (until Feb 17, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $8.3B | $7.8B | $7.0B | $7.9B | $7.8B |
| Operating income | $3.5B | -$10.4B | $2.6B | $2.0B | $3.3B |
| Net income | $2.4B | -$10.5B | $2.0B | $2.2B | $3.1B |
| Diluted EPS | $1.94 | -$8.45 | $1.61 | $1.74 | $2.43 |
| Operating cash flow | $5.0B | $3.6B | $2.5B | $3.3B | $4.1B |
| Free cash flow | $4.8B | $3.4B | $2.4B | $3.1B | $4.0B |
| Total assets | $51.4B | $49.4B | $56.3B | $59.0B | $58.5B |
| Stockholders' equity | $13.0B | $11.8B | $23.5B | $22.7B | $21.5B |
| Cash and investments | $6.4B | $3.2B | $8.6B | $10.6B | $9.4B |
| Total debt | $26.2B | $26.2B | $22.2B | $25.5B | $24.9B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
May 20, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1001 Gilead Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.